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Summary
Background: Malignant melanoma is a highly aggres-
sive neoplastic disease whose incidence is increasing
rapidly. In recent years, the use of interferon α (IFNα)
has become the most established adjuvant immuno-
therapy for melanoma of advanced stage. IFNα is a po-
tent inhibitor of melanoma cell proliferation, and the
signal transducer and activator of transcription STAT1
is crucial for its antiproliferative action. Although ad-
vanced melanomas clinically resistant to IFNα are fre-
quently characterized by inefficient STAT1 signaling,
the mechanisms underlying advanced-stage interferon
resistance are poorly understood.
Results: Here, we demonstrate that IFNα activates
STAT5 in melanoma cells and that in IFNα-resistant
cells STAT5 is overexpressed. Significantly, the knock-
down of STAT5 in interferon-resistant melanoma cells
restored the growth-inhibitory response to IFNα. When
STAT5 was overexpressed in IFNα-sensitive cells, it
counteracted interferon-induced growth inhibition. The
overexpressed STAT5 diminished IFNα-triggered STAT1
activation, most evidently through upregulation of the
inhibitor of cytokine-signaling CIS.
Conclusions: Our data demonstrate that overexpres-
sion and activation of STAT5 enable melanoma cells to
overcome cytokine-mediated antiproliferative signal-
ing. Thus, overexpression of STAT5 can counteract
IFNα signaling in melanoma cells, and this finally can
result in cytokine-resistant and progressively growing
tumor cells. These findings have significant implica-*Correspondence: claudia.wellbrock@icr.ac.uk
4 Present address: Institute of Cancer Research, 237 Fulham Road,
London SW3 6JB, United Kingdom.tions for the clinical failure of IFNα therapy of advanced
melanoma because they demonstrate that IFNα in-
duces the activation of STAT5 in melanoma cells, and
in STAT5-overexpressing cells, this contributes to IFNα
resistance.
Introduction
Over the past few decades, the incidence of malignant
melanoma has increased at a rate that exceeds that
of any other solid tumor. With a limited efficiency of
chemotherapy, the use of interferon α (IFNα) has be-
come the most established adjuvant immunotherapy
for melanoma of advanced stage. However, the results
of multiple clinical trials are controversial and difficult
to interpret partly because of a great heterogeneity be-
tween the parameters of the trials [1, 2].
IFNα mediates its effects through activation of the
janus kinases JAK1 and TYK2, which in turn phosphor-
ylate and activate the signal transducers and activators
of transcription: STAT1, STAT2, and STAT3. Activation
of these latent transcription factors results in the forma-
tion of STAT homo- and heterodimers, their nuclear
translocation, and trans-activation of the interferon-
stimulated genes (ISGs) [3]. ISGs are characterized by
the presence of γ activating sequences (GAS) and/or
interferon response elements (ISRE) in their promoters.
GAS elements are the targets for STAT homo- or hetero-
dimers, whereas ISRE sites are bound by the interferon-
stimulated gene factor 3 (ISGF3) in response to IFNα
[4]. ISGF3 is a trimeric complex and consists of STAT1,
STAT2, and the interferon-stimulated gene factor 3γ
(p48/ISGF3γ/IRF-9). Although IFNα activates gene ex-
pression through GAS elements, the major part of the
IFNα-induced gene expression is brought about by
ISGF3’s binding to ISRE sites [5]. The essential role of
STAT1 in the mediation of an IFNα response (and, in
general, interferon signaling) is seen in STAT1 (−/−)
mice, which are unresponsive to interferons but remain
responsive to other cytokines [6].
In addition to immunomodulatory activity, IFNα has a
direct growth-inhibiting effect on melanoma cells [7, 8].
However, cell lines originating from melanoma of ad-
vanced stage are frequently unresponsive to the growth-
inhibiting effect of IFNα. Such interferon-resistant cells
often show defective JAK-STAT signaling, which corre-
lates either with a significant reduction in the level of
STAT1 protein or inefficient phosphorylation of STAT1
[7, 9, 10]. However, whereas inefficient STAT1 phos-
phorylation in response to IFNα and reduced STAT1
levels have also been observed in melanoma patients
[9, 11, 12], other studies describe only slight variations
in STAT1 expression levels in melanoma biopsies and
no loss of function in interferon-resistant cell lines [13,
14]. Thus, the mechanism underlying the cellular IFNα
resistance seems to be complex. For the successful
application of IFNα in melanoma therapy, it is, however,
important to understand the specific function of this
interferon in melanoma cells.
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1630It is noteworthy that stimulation of interferon recep-
tors can also lead to the activation of STAT5 [15–17]. In
contrast to STAT1, STAT5 is involved in mitogenic as
well as in antiapoptotic signaling [6]. STAT5 is constitu-
tively active in a variety of transformed cells, which in-
clude Xiphophorus melanoma cells [18–20]. Although
this suggests an involvement of STAT5 in promoting on-
cogenesis in pigment cells, nothing is known about its
functional role in human melanoma development.
To investigate whether STAT5 plays a role in the de-
velopment of melanoma, we analyzed its expression in
melanoma biopsies and several human melanoma cell
lines. STAT5 was found to be overexpressed in IFNα-
resistant cell lines and in situ in advanced melanoma
lesions. Overexpression of STAT5 in IFNα-sensitive cells
revealed that STAT5 can counteract the STAT1-medi-
ated IFNα response by upregulating the cytokine inhibi-
tor CIS. Furthermore, depletion of STAT5 from IFNα-
resistant cells by RNA interference (RNAi) resulted in
enhanced sensitivity toward IFNα-induced growth inhi-
bition. In summary, our findings strongly suggest a role
for STAT5 in the frequently found clinical resistance of
advanced melanoma to interferon.
Results
STAT5 Expression in Melanocytic Lesions
Correlates with Tumor Progression
In human skin, STAT5 expression was detected speci-
fically in melanocytes located in the basal membrane
of the epidermis (STAT5 FITC, Figure 1A), where it colo-
calized with the melanocyte differentiation antigen
MART-1. No significant expression of the STAT protein
was seen in surrounding keratinocytes, and this was
confirmed in the keratinocyte cell line HaCat (Figure
1B). Both STAT5a and STAT5b were expressed in pri-
mary human melanocytes (mel 1043 and mel 775) to a
level similar to that found in the human primary mela-
noma cell line IFB, whereas STAT5 expression was in-
creased in Mel19 metastatic melanoma cells (Figure
1B). STAT1 was expressed in melanoma cells, in mela-
nocytes, and in keratinocytes (Figure 1B), underlining
the specificity of STAT5 expression in pigment cells of
the epidermis.
Staining of melanocytic skin lesions with anti-STAT5
detected the expression of STAT5 in both benign and
neoplastic melanocytic lesions (Figures 1C and 1D).
Because STAT5 expression is not restricted to melano-
cytic cells but can also be seen in leukocytes, double
staining for STAT5 and the melanocyte differentiation
antigen MART-1 was performed. This confirmed that
the majority of STAT5-expressing cells within the tested
lesions were of melanocytic origin (Figure 1D). Strik-
ingly, the number of STAT5-expressing cells was signifi-
cantly elevated in neoplastic lesions compared to be-
nign nevi (Figures 1C and 1D, p % 0.001). Analysis of
the cellular distribution in MART-1-positive cells re-
vealed that although the relative amount of cytoplasmic
STAT5 to nuclear-localized STAT5 did not significantly
change during tumor progression, the absolute number
of cells showing intranuclear localization increased
from benign to neoplastic and primary to metastatic
lesions (Figure 1D).
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nTAT5 Expression Is Enhanced in Interferon-
esistant Melanoma Cells
nalysis of STAT5 protein levels in various melanoma
ell lines showed a significantly enhanced expression
n D10, MM96, Mel19, and WM164 cells (Figure 2A).
wo of the STAT5-overexpressing cell lines, D10 and
M96, are known to be resistant toward interferon-
nduced growth inhibition [7, 9], and our analysis re-
ealed a noticeable correlation of STAT5 overexpres-
ion with IFNα resistance (Figures 2A and 2B). Notably,
TAT1 was expressed in all cell lines regardless of their
eactivity toward IFNα, and although slight differences
n the protein level of STAT1, as well as those of STAT2
nd STAT3 were observed, they did not strictly correlate
ith interferon resistance (Figures 2A and 2B).
In all interferon-resistant cell lines, IFNα stimulation
esulted in phosphorylation of JAK1 and TYK2 (Figure
C), indicating that the receptors are active. However,
hereas STAT1 became strongly phosphorylated in re-
ponse to IFNα in all sensitive cell lines and in human
rimary melanocytes, the STAT1 phosphorylation level
as reduced or completely abolished in three (MM96,
el19, and WM164) of four resistant cell lines (Figure 2D).
Because interferon-resistant cell lines appear to
verexpress STAT5, we asked both whether STAT5
ight interfere with IFNα induced STAT1 activation and
hether STAT5 plays a significant role in IFNα signaling
n melanoma cells.
ctivation of STAT1 Is Required for an Efficient
FN Response in Melanoma Cells
or our further experiments, we chose A375 cells be-
ause they showed the highest IFNα sensitivity in our
ands. Stimulation of A375 cells with IFNα resulted in
hosphorylation of STAT1 (see Figure 2D) and nuclear
ranslocation (Figure 3A). IFNα also induced binding of
he STAT1-containing IGSF3 complex to ISRE se-
uences (Figure 3B). Already 30 min after addition of
FNα, all three components of IGSF3 were found to bind
o the ISRE sequence (Figure 3B). However, after 22
r IFNα stimulation, the amount of ISRE bound STAT1,
TAT2, and p48 was considerably enhanced. This de-
ayed increase correlated with the trans-activation of an
SRE-containing promoter, which was weak (1.3-fold)
fter 3 hr but much stronger (7.3-fold) after 22 hr (Figure
C) and was also reflected in the induction of
PNPaseold-35 (Figure 3D), an interferon-inducible gene
hose expression is regulated through an ISRE site in
elanoma cells [21].
The importance of STAT1 for IFNα signaling was seen
n A375 cells expressing a dominant-negative STAT1, in
hich tyrosine 701 is mutated to phenylalanine [22] and
hich therefore shows no significant tyrosine phos-
horylation in response to IFNα (Figure 3E, lower panel).
he lack of STAT1 activation in STAT1F-expressing cells
esulted in a substantial reduction in IFNα-induced
rowth inhibition when compared to mock transfected
r STAT1/WT-expressing cells (Figure 3F), clearly dem-
nstrating the importance of STAT1 for the IFNα re-
ponse in melanoma cells. Our data also suggest that
rolonged STAT1 activation is required for significant
nduction of ISRE-driven gene expression in mela-
oma cells.
STAT5 Activation in Melanoma
1631Figure 1. Expression of STAT5 in Normal Human Skin, Nevi, and Melanoma
(A) A section of normal human skin stained with anti-MART-1 (red) and anti-STAT5 (green).
(B) Melanoma lines Mel19 and IFB, human primary melanocytes mel1043 and mel755, and HaCat cells were analyzed with anti-STAT5 and
anti-STAT1.
(C) Sections of benign nevi, primary cutaneous melanoma, or skin metastases were stained with anti-STAT5 using AEC (red). Slides were
counterstained with hematoxylin (blue nuclei). Examples of nuclear STAT5 staining are indicated by arrows.
(D) Sections of benign nevi, primary cutaneous melanoma, or skin metastases were stained with anti-MART-1 (Cy3-red) and anti-STAT5 (FITC-
green). The frequency of STAT5 staining in MART-1-positive cells was classified as follows: 0 = none, 1 = <10%, 2 = <30%, 3 = <60%, and
4 = >60%.
Current Biology
1632Figure 2. STAT5 Overexpression Correlates
with IFNα Resistance
(A) Human melanoma cell lines were ana-
lyzed for STAT protein expression with the
indicated antibodies. Analysis of ERK2 ex-
pression was used as a loading control.
(B) Melanoma cell lines were cultured for 4
days in IFNα (1000 U/ml) containing medium.
Control cells were grown without IFNα. After
4 days, cells were counted and the cell num-
ber of untreated cells was set 100%. The er-
ror bars above the columns indicate stan-
dard deviation (SD) from the mean.
(C) Melanoma cells were stimulated with
IFNα for 30 min, and the phosphorylation of
JAK1 and TYK2 was analyzed with phospho-
specific antibodies. Analysis of ERK2 ex-
pression was used as a loading control.
(D) The indicated cell lines were stimulated
with IFNα for the indicated times, and the
phosphorylation of STAT1 was analyzed with
anti-phospho(Y701)STAT1. The amount of
total STAT protein was determined with
anti-STAT1.Overexpression of STAT5 Reduces the IFN
Response in Melanoma Cells
Stimulation of A375 cells with IFNα also resulted in
phosphorylation of STAT5 (Figure 4A), its nuclear accu-
mulation (not shown), and specific DNA binding to GAS
sequences (GAS-WT; Figure 4B). Furthermore, a repor-
ter construct containing a STAT5-responsive promoter
became activated by IFNα. Activation was seen after 3
hr, whereas after 22 hr, the promoter induction was al-
most back to basal level (Figure 4C), suggesting that
STAT5-induced promoter activation in response to IFNα
is an early event.
Strikingly, transient overexpression of STAT5A or
STAT5B clearly had a significant inhibitory effect on the
IFNα induction of an ISRE-containing promoter (Figure
4D). STAT1, on the other hand, did not suppress IFNα-
induced induction of this promoter. To further analyze
effects of STAT5 overexpression, we established A375
cells stably expressing STAT51*6 (Figure 4E), a STAT5A
version bearing mutations (H299R, S711F) that stabilize
the tyrosine-phosphorylated form of the protein [23].
However, basal constitutive tyrosine phosphorylation of
STAT51*6 was low in A375-1*6 cells (Figure 4F), reflect-
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tng a low basal activity of the respective upstream ki-
ases. Stimulation of A375-1*6 cells with IFNα resulted
n phosphorylation of STAT51*6. This phosphorylation
as stronger, lasted longer than that of endogenous
TAT5 in A375 cells, and resembled the strong phos-
horylation, seen in the resistant cell lines D10, MM96,
el19, and WM164, of STAT5 (Figure 4F and Figure S1
n the Supplemental Data available with this article
nline).
As seen after transient overexpression of STAT5,
uciferase induction from an ISRE-containing promoter
as greatly reduced in A375-1*6 cells compared to
ontrol A375svneo cells even at high IFNα concentra-
ions (Figure 4G). The suppression of ISRE-mediated
ranscription was also seen when IFNα-induced
PNPaseold-35 expression was analyzed in A3751*6
ells compared to A375 cells or STAT1-overexpressing
375 cells (Figure 4H). Moreover, in STAT51*6-express-
ng cells, the IFNα-induced growth-inhibition response
as considerably reduced (Figure 4I). Together, these
ata suggest that overexpression of STAT5 can antago-
ize IFNα-induced gene expression and growth inhibi-
ion in melanoma cells.
STAT5 Activation in Melanoma
1633Figure 3. STAT1 Activation Is Required for
IFNα Signaling
(A) A375 cells were either stimulated with
IFNα for 30 min or left untreated (−). Fixed
cells were stained with anti-STAT1 and Cy2-
conjugated secondary antibodies.
(B) Cellular extracts of A375 cells either stim-
ulated with IFNα for the indicated times
or left untreated (−) were incubated with oli-
gonucleotides carrying ISRE sites. Bound
proteins were eluted and analyzed with anti-
STAT1, anti-STAT2, and anti-p48 on a west-
ern blot.
(C) Luciferase expression from an ISRE-con-
taining promoter or the empty vector pGL2
was measured after 3 hr or 22 hr of IFNα
stimulation of A375 cells. Luciferase activi-
ties were normalized to β-galactosidase
activities, and error bars represent SD from
the mean.
(D) A375 cells stimulated with IFNα for the in-
dicated times were analyzed for hPNPaseold-35
expression by RT-PCR. Amplification of
GAPDH served as control.
(E) A375 cell lines expressing either HA-
tagged STAT1 (STAT1WT) or an HA-tagged
dominant-negative mutant STAT1F were
stimulated with IFNα for the indicated times
and analyzed with anti-phospho(Y701)-
STAT1. The amount of STAT1WT and STAT1F
protein was determined with anti-HA. Con-
trol (mock) cells had been transfected with
the empty vector.
(F) A375 cells, mock-transfected cells, and
STAT1WT- or STAT1F-expressing cells were
cultured for 4 days in IFNα-containing me-
dium before they were counted. Control cells
were grown in IFNα-free medium. The error
bars above the columns indicate SD from
the mean.STAT5 Counteracts IFN-Induced STAT1 Activation
and Upregulates the Cytokine Inhibitor CIS
Whereas STAT1 became phosphorylated in control
transfected A375svneo cells with similar intensity and
duration compared to the parental cells (compare with
Figure 2D), its phosphorylation was weaker and almost
back to basal level after 6 hr of IFNα stimulation in
A375-1*6 cells (Figure 5A). Notably, this activation pro-
file strongly resembled the profile observed in the resis-
tant MM96 and Mel19 cells (see Figure 2D).
Analysis of the IFNα-induced expression of suppres-
sors of cytokine signaling (SOCS) revealed no differ-
ences in the induction of SOCS1 and SOCS2 (not
shown), but the induction of SOCS3 expression by IFNα
was significantly reduced in STAT51*6-expressing A375
cells (Figure 5B). Most strikingly, whereas the STAT5
target gene CIS [24] was induced very transiently by
IFNα in A375 and A375svneo cells (Figure 5B), its ex-
pression was induced to a high level and persisted at
least 6 hr in STAT5-overexpressing A375-1*6 cells (Fig-
ure 5B). This was reflected at the protein level, and in
A375-1*6 cells, a strong increase of CIS protein was
detectable up to 22 hr (Figure 5C). Basal CIS expres-
sion in interferon-resistant and -sensitive cells did not
differ significantly although SK-Mel28 cells expressedvery low levels of the protein (Figure 5D). However, in
contrast to the interferon-sensitive cells A375, IFB, SK-
Mel28, and Bro, CIS expression was significantly in-
duced by IFNα in the resistant cell lines (Figure 5D).
When CIS was overexpressed in interferon-sensitive
A375 cells, the IFNα-stimulated induction of an ISRE-
containing promoter was suppressed (Figure 5E), sug-
gesting that enhanced CIS expression can counteract
IFNα-induced signaling.
To fully assess the consequence of enhanced CIS ex-
pression for IFNα-mediated growth inhibition, we ana-
lyzed the effect of CIS overexpression on the interferon
response of A375 cells in a colony-formation assay. To
further compare the effect produced by CIS with the
capacity of STAT5 to counteract IFNα-mediated growth
inhibition, we analyzed overexpression of STAT5 as well
as STAT51*6 in the same assay. In agreement with the
results of Figure 4I, overexpression of STAT51*6 signifi-
cantly enhanced the number of colonies formed by
A375 cells in the presence of IFNα when compared to
cells transfected with an empty vector (Figure 5F).
Strikingly, also wild-type STAT5A had a significant ef-
fect on the interferon-mediated growth inhibition (Fig-
ure 5F), indicating that STAT5 overexpression alone is
sufficient to antagonize the IFNα response. Also, over-
Current Biology
1634Figure 4. STAT5 Is Activated by IFNα in Mela-
noma Cells
(A) A375 cells were stimulated with IFNα for
the indicated times and analyzed for phos-
pho(Y694)-STAT5 and total STAT5.
(B) A375 cells were either left untreated (−)
or stimulated with IFNα for 30 min. Cellular
extracts were analyzed for specific DNA
binding activity by incubation with oligonu-
cleotides carrying either a GAS (GAS WT) se-
quence or a mutated binding deficient se-
quence (GAS MUT). Bound proteins were
analyzed with anti-STAT5.
(C) A375 melanoma cells were transfected
with either a luciferase construct containing
six STAT5 binding sites (STAT5-RE TK luc) or
a control vector (pGL2), and luciferase in-
duction by IFNα was measured after 24 hr.
(D) A375 melanoma cells were transfected
with an ISRE-containing luciferase construct
and with plasmids for STAT5a, STAT5b,
STAT1, or an empty vector. Twenty-two
hours after the transfection, luciferase in-
duction was measured. Luciferase activities
in (C) and (D) were normalized to β-galacto-
sidase activities, and error bars represent SD
from the mean.
(E) Analysis of STAT5 expression in parental
A375, control A375svneo, and A375-1*6 cells
with anti-STAT5a.
(F) Tyrosine phosphorylation of STAT51*6 be-
fore and after 10 min of stimulation with IFNα
was detected by immunoprecipitation with a
STAT5A specific antibody and western-blot
analysis with anti-phosphotyrosine. The
membrane was reprobed with anti-STAT5A.
(G) A375svneo and A375-1*6 cells were
transfected with an ISRE-containing lucifer-
ase construct and stimulated with the indi-
cated IFNα concentrations. After 24 hr, lucif-
erase induction was measured. The error
bars above the columns indicate SD from
the mean.
(H) A375, A375-1*6, and STAT1WT-overex-
pressing A375 cells stimulated with IFNα
for the indicated times were analyzed for
hPNPaseold-35 expression by RT-PCR. Ampli-
fication of GAPDH served as control.
(I) A375svneo and A375-1*6 cells were cul-
tured for 4 days in IFNα-containing medium
before they were counted. The error bars
above the columns indicate SD from the
mean.expression of CIS affected the interferon response of
A375 cells (Figure 5F), but the effect reached only 50%
of the effect produced by STAT5, suggesting that STAT5
antagonizes IFNα-induced growth inhibition through
additional factors.
Depletion of STAT5 Enhances the IFN Response
of Melanoma Cells
To establish conclusively its function in interferon sig-
naling in melanoma cells, we depleted STAT5 with a
specific small interfering RNA (siRNA) during IFNα stim-
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tlation. Treatment of A375 cells with the STAT5-specific
iRNA resulted in efficient depletion of the STAT pro-
ein, whereas a control siRNA (con) did not affect STAT5
xpression (Figure 6A). The STAT5-specific siRNA also
roduced a significant reduction in the amount of the
ranscription factor in the STAT5-overexpressing IFNα-
esistant MM96 cells (Figure 6A).
Depletion of STAT5 in MM96 cells had a significant
ffect on STAT1 activation in response to IFNα (Figure
B). Whereas in untreated cells and cells treated with
he control siRNA, STAT1 phosphorylation was almost
STAT5 Activation in Melanoma
1635Figure 5. Overexpression of STAT51*6 in Human Melanoma Cells Leads to an Altered Expression of IFNα Target Genes
(A) A375svneo and A375-1*6 cells were stimulated with IFNα for the indicated times and analyzed with anti-phospho(Y701)STAT1. The mem-
brane was reprobed with anti-STAT1.
(B) A375, A375svneo, and A375-1*6 cells were stimulated with IFNα for the indicated times and analyzed for CIS and SOCS3 expression by
RT-PCR. Amplification of GAPDH served as control.
(C) Analysis of CIS protein expression in A375, A375svneo, and A375-1*6 cells stimulated with IFNα for the indicated times.
(D) Analysis of CIS protein expression in the indicated cell lines stimulated with INFα for 3 hr or 6 hr.
(E) A375 cells were transfected with a luciferase construct containing five ISRE sites and expression plasmids for CIS, STAT1, or an empty
vector (control). Twenty-two hours after the transfection, luciferase induction was measured.
(F) A375 cells were transfected with a Hygromycin resistance plasmid and either an empty vector or a CIS, STAT5A, or STAT51*6 expression
vector. Cells were selected for Hygromycin resistance and stained for colonies with crystal violet 19 days after the transfection. Quantification
was performed by measuring the absorbance of resolubilized crystal violet. A representative stained cell image is shown on top of the graph.back to basal level 6 hr after IFNα stimulation, reduc-
tion of STAT5 levels in MM96 cells resulted in a more
prolonged activation of STAT1 in response to the cy-
tokine (Figure 6B). An even more striking consequence
of STAT5 depletion in MM96 cells was apparent when
the responsiveness to the antiproliferative potential ofIFNα was examined. Whereas MM96 cells treated with
the control siRNA (con) were completely resistant to the
growth-inhibitory effect of IFNα, the proliferation of
cells treated with the STAT5-specific siRNA was con-
siderably inhibited (Figure 6C). Similar effects were
seen in the resistant cell line Mel19 (data not shown).
Current Biology
1636Figure 6. Depletion of STAT5 in Human Melanoma Cells Results in
INFα Sensitivity
(A) A375 and MM96 cells were left untreated (−) or were transfected
with either a control siRNA (con) or a STAT5-specific siRNA. Sev-
enty-two hours after the transfection, the expression of STAT5 was
analyzed by western blotting with anti-STAT5. Analysis of ERK2 ex-
pression was used as a loading control.
(B) MM96 cells were left untreated (−) or were transfected with
either a control siRNA or a STAT5-specific siRNA. Sixty-four hours
after transfection, cells were stimulated with IFNα for the indicated
times and analyzed for STAT1 phopshorylation with anti-phospho
(Y701) STAT1. The amount of total STAT1 protein was determined
with an anti-STAT1 antibody, and STAT5 expression in control cells
and STAT5-siRNA-treated cells was analyzed with anti-STAT5.
Analysis of ERK2 expression was used as a loading control.
(C) A375 and MM96 cells were transfected with either a control
siRNA (con) or a STAT5-specific siRNA. Thirty-six hours after trans-
fection, the cells were stimulated with IFNα for 24 hr. For the last 4
hr, 3H-thymidine was added, and incorporated 3H-thymidine was
quantified by liquid scintillation counting. The error bars above the
columns indicate SD from the mean.
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Malignant melanoma is a highly aggressive and increas-
ingly common disease. Treatment of metastatic mela-
noma is notoriously difficult and usually ineffective, fre-
quently because of the acquisition by melanoma cells
l
s
s
t
s
e
iof resistance to growth-inhibitory cytokines [7, 8, 25].ecause STAT1 is essential for the mediation of anti-
roliferative effects brought about by interferons, it is
ot surprising that deficient STAT1 activation is corre-
ated with interferon resistance in melanoma [11, 12].
We present here several lines of evidence for a role of
TAT5 in melanoma development and its involvement
n interferon resistance. We have shown that STAT5 is
verexpressed in cell lines derived from advanced mel-
noma and that nuclear-localized STAT5 increased with
umor progression in melanoma biopsies. We also
ound that STAT5 was localized in the cytoplasm in mel-
nocytes and melanoma cells derived from a primary
elanoma (IFB and A375 cells), whereas predominantly
uclear localization was seen in all other melanoma cell
ines (Figure S2 and data not shown). Because nuclear
ranslocation of STATs is implicated in their cellular acti-
ation, this suggests constitutive activation of STAT5 in
alignant melanoma. However, future studies involving
nalysis of STAT5 phosphorylation are required to fully
stablish the state of STAT5 activation in melanoma.
We found that STAT5 overexpression correlated with
FNα resistance in melanoma cell lines. Significantly,
ctopic overexpression of STAT51*6 as well as wild-
ype STAT5 severely reduced the ability of IFNα to
nhibit proliferation in an IFNα-sensitive cell line. More-
ver, depletion of STAT5 in IFNα-resistant cells dramati-
ally enhanced the responsiveness to IFNα. This
trongly supports the notion that deregulation of STAT5
ctivity is likely to make a significant contribution to the
cquisition of IFNα resistance.
STAT1 activation is crucial for IFNα-induced growth
nhibition in melanoma cells [7, 9] but was found to be
nhibited by the overexpression of STAT51*6. Because
TAT1 is an essential component of ISGF3, the tran-
cription factor that binds to the ISRE in interferon-
nduced genes [4], ISRE-dependent transcription was
trongly suppressed in STAT51*6-expressing cells. We
ound that in melanoma cells, ISGF3-mediated tran-
cription is a late event that would require sustained
TAT1 activation. However, activation of STAT5 resulted
n abrogation of sustained STAT1 activation. This was
ufficient to affect ISGF3-driven transcription as seen in
he suppression of hPNPaseold-35 expression. Notably,
nhanced hPNPaseold-35 expression strongly inhibits
elanoma cell growth [26], and the suppression of
PNPaseold-35 levels will counteract this antiprolifera-
ive effect.
Although STAT51*6 became activated by IFNα imme-
iately after receptor stimulation, its inhibitory effect on
TAT1 became apparent only in a later phase of activa-
ion, suggesting the involvement of the suppressor of
ytokine signaling (SOCS/CIS) factors. A mutual regula-
ion of STATs on the level of SOCS/CIS factors has been
ound in a variety of cell systems where the suppression
f STAT1 tyrosine phosphorylation blocks interferon-
nduced cellular responses [27, 28]. In STAT51*6-overex-
ressing cells, impaired STAT1 activation was corre-
ated with a reduced SOCS3 (CIS3) expression and a
trongly enhanced CIS (CIS1) expression. We demon-
trate here that overexpression of CIS contributes to
he effect of STAT5 and leads to a significant suppres-
ion of IFNα-induced transcription. Furthermore, over-
xpression of CIS in IFNα-senstitive cells reduced the
nterferon response of the cells. This suggests a new
role for CIS in the acquisition of interferon resistance in
STAT5 Activation in Melanoma
1637melanoma. However, the effect brought about by CIS
accounted only for 50% of the effect caused by STAT5,
which suggests that the STAT5-induced IFNα resis-
tance involves the activation of additional factors.
Although both CIS and SOCS3 inhibit cytokine-induced
signaling, they differ in the way they act. SOCS3 affects
the activity of JAK kinases, and CIS inhibits the binding
of STATs to the activated tyrosine-phosphorylated re-
ceptor [29]. Interestingly, we and others have demon-
strated that STAT5, but neither STAT1 nor STAT3, can
become activated independently from receptor phos-
phorylation [30, 31]. On the other hand, activation of
STAT1 by the IFN receptor is strictly dependent on re-
ceptor phosphorylation [32]. Thus, STAT1 activation
might be inhibited by overexpression of CIS, whereas
STAT5 could still become activated by the receptor.
Another possibility by which overexpression of STAT5
could affect the activation of STAT1 could be competi-
tion of STAT5 with STAT1 for activation by the receptor.
Accordingly, in cells that overexpress STAT51*6, STAT5
phosphorylation is much stronger (see Figures S1) and
STAT1 activation is decreased. Also, when STAT5 ex-
pression was lowered by RNAi, its activation was re-
duced and STAT1 activation was increased (see Figure
6). However, the most striking differences in STAT1 acti-
vation between interferon-resistant and -sensitive cells
were observed at later time points (3–6 hr), suggesting
that reduced STAT1 activity is rather due to enhanced
STAT5 downstream signaling than to overexpressed
STAT5 preventing STAT1 activation by the receptor
through competition. Furthermore, we found that over-
expression of either wild-type or dominant-negative
STAT1 had no significant effect on the activation of
STAT5 (not shown). Similarly, no increase in interferon-
induced STAT5 activation was found in T cells from
STAT1 (−/−) mice when compared to normal T cells [33],
and this points to no influence of STAT1 expression
levels on STAT5 activation by the interferon receptor.
Together, these data suggest that the effects we ob-
served are not due to competition at the receptor level,
but further studies are required to fully address this
issue.
Conclusions
The data presented here show that in melanoma cells,
STAT1 and STAT5 exhibit a functional antagonism;
whereas STAT5 promotes cell growth and protects the
cells from the inhibitory effect of IFNα, STAT1 contrib-
utes to growth inhibition. Thus, a tight regulation of
STAT activation and signaling seems to be a critical
step in the cytokine-mediated growth control of mela-
noma cells. Our findings suggests that loss of STAT1
activity but gain of STAT5 activity can lead to an imbal-
ance in this regulation and enables melanoma cells to
overcome cytokine-mediated antiproliferative signal-
ing, thus contributing to melanoma development and
progression.
Experimental Procedures
Cell Culture, Generation of Cell Lines,
and Colony-Formation Assay
A375 (ATCC#CRL1619), SK-Mel 28 (ATCC#HTB72), D10, Mel19,
AIFB, Bro, and STAT1- and STAT1F-expressing A375 cells [34] were
cultured in RPMI/10% FCS; WM164 and MM96 were grown inDMEM/10% FCS. Human primary melanocytes were cultured in
DMEM/10% FCS containing 200 nM TPA, 1.2 nM cholera toxin, and
0.3 nM bFGF. For all experiments, if not indicated otherwise, the
medium was replaced by DMEM/1% FCS for 24 hr before the cells
were stimulated with IFNα at a concentration of 1000 U/ml. For the
generation of A375 cells expressing STAT51*6 (a kind gift from T.
Kitamura [23]), the cells were transfected with prk5STAT51*6 and
selected for G418 (1 mg/ml) resistance. Stable clones were ana-
lyzed by western-blot analysis with anti-STAT5a. For the colony-
formation assay, cells were transfected in triplicates with 1 g
expression plasmid plus 0.1 g pCDNA3.1/Hygro and selected in
Hygromycin (0.5 mg/ml) for 5 days. After this selection, cells were
either treated with IFNα or left untreated for another 14 days before
colonies were stained with crystal violet.
Cell Lysis, Immunoprecipitation, Western Blotting,
and Antibodies
Cells were rinsed twice with cold PBS and lysed in Triton lysis
buffer, and immunoprecipitation and western blotting were per-
formed as described [19]. The following antibodies were used: anti-
STAT5b (C-17; crossreacts with STAT5A), anti-STAT5a (L-20;
STAT5A specific), anti-STAT1 (E-23), anti-STAT3 (C-20), anti-p48/
ISGF3γ (C-20), anti-CIS (C-20), and anti-ERK2 (C-14) were from
Santa Cruz Biotechnology. Anti-phospho (Y701) STAT1 and anti-
Tyk2 were from UBI; anti-STAT2, anti-JAK1, and anti-phosphotyro-
sine (PY20) were from BD Transduction Laboratories. Anti-phos-
pho(Y1022/1023)-JAK1, anti-phospho(Y1054/1055)-TYK2, and anti-
phopsho(Y694)-STAT5 were from Cell Signaling.
Immunofluorescence and Immunohistological
Analysis of Melanoma Biopsies
Methanol/acetone fixed cells were blocked with 1% BSA/PBS and
incubated with either anti-STAT5 (C-17) or anti-STAT1 (E-23) and
with either Cy2- or Cy3-conjugated anti-rabbit IgG (Dianova). Cells
were embedded in mounting medium containing DAPI. For tissue
samples, frozen sections were dried overnight and fixed in acetone.
All incubation steps including anti-MART-1 (1:150; clone 361M, Bio-
site), Cy3-conjugated anti-mouse IgG (Dianova), and finally FITC-
conjugated anti-STAT5 (1:250; C-17, Santa Cruz Biotechnology)
were performed at room temperature (RT). Slides were mounted in
vectashield and analyzed with a Leica confocal microscope. Chi-
square tests were used to compare the proportions of STAT5-posi-
tive cells in benign and malignant lesions. For immunohistology,
frozen sections were fixed in acetone followed by quenching of
endogenous peroxidase with 0.03% H2O2 and blocking of collage-
nous elements with 10% BSA. Serial sections were incubated for
30 min with biotinylated antibodies at predetermined dilutions (usu-
ally 20 g/ml). Subsequently, the streptavidin-peroxidase complex
(DAKO) was applied for 30 min, followed by 15 min incubation with
the chromogen AEC (DAKO). Slides were counterstained with he-
matoxylin (DAKO) and mounted in aquatex (Merck Eurolab).
Preparation of Cell Extracts and STAT5 DNA Binding
Cell extracts were prepared by four freeze-thaw cycles in low salt
lysis buffer (20 mM HEPES, pH 7.9, 20% glycerol, 100 mM NaCl,
50 mM KCl, 1 mM EDTA, 1 mM DTT, 1 mM PMSF, 1 mM Na3VO4,
10 g/ml leupeptin, and 10 g/ml aprotinin). The cleared superna-
tant was incubated with M280-Streptavidin Dynabeads (Dynal) car-
rying either multiple ISRE (5#-GATCCAGGCTCCCGGGAAAGCGAA
ACCTAAACAGTGGCGC-3#) or GAS elements (5#-GATCAGATTTT
GGAAATCAATCC-3#) or a mutated GAS sequence (5#-GATCA
GATTTATTTTAATTCAATCC-3#). Bound proteins were eluted and
analyzed by western blotting.
Transfections and Luciferase Reporter Assays
A375 cells were transfected with 1 g luciferase construct, 0.4 g
expression vector, and 0.4 g pSV-β-Galactosidase (Promega) with
Lipofectamine (Invitrogen). After 24 hr, cells were lysed in RLB
buffer (Promega) and analyzed for luciferase activity. The con-
structs were pGL2, 5xISRE-TK-LUC (a gift from T. Spencer [35]),
STAT5RE-TKluc, pXM-STAT5a and STAT5b (kindly provided by R.
Moriggl [36]), pcDNAmyc-CIS1 (a kind gift from A. Yoshimura [37]),
and pCAGGSNeoSTAT1 [22]. Each experiment was performed at
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1638least three times, and luciferase expression was corrected with
β-galactosidase values as a covariate.
RT-PCR Analysis
RNA was isolated with TRIZOL reagent (Invitrogen). First-strand
cDNA synthesis was done with 1 g total RNA and random hexa-
nucleotides. The respective genes were amplified with a number of
cycles, where amplification was still linear and analyzed on an
agarose gel. The primers were the following: for cis, 5#-CTGCTGTG
CATAGCCAAGACGTTC-3# and 5#-CAGAGTTGGAAGGGGTACTGT
CGG-3#; for socs3, 5#-GGTCACCCACAGCAAGTTTCC-3# and 5#-
GTCCAGGAACTCCCGAATGGG-3#; for hPNPaseold-35, 5#-AAGA
GAACTTGGGCATGGTG-3# and 5#-TTTGCCACTGAAGCTTGTTG-
3#; and for gapdh 5#-CGGAGTCAACGGATTTGGTCGTAT-3# and 5#-
AGCCTTCTCCATGGTGGTGAAGAC-3#.
RNA Interference and Thymidine Incorporation
Melanoma were seeded at 2.2 × 103 cells per well of a 6-well plate
the day before transfection. Cells were transfected with 120 nM
STAT5-specific siRNA (5#-AACGCCACCAUCACGGACAUU-3#) or
120 nM control siRNA (5#-AAGUCCAUGGUGACAGGAGAC-3#) in 1
ml OPTIMEM with 4 l Lipofectamine. After 5 hr, 1 ml of DMEM
containing 10% FCS was added, and the cells were cultured o/n.
Then, the medium was replaced by DMEM/1% FCS for 24 hr before
the cells were stimulated with IFNα for 24 hr. For the last 4 hr, 3H-
thymidine (0.4 Ci/ml) was added, and incorporated 3H-thymidine
was quantified by liquid scintillation counting.
Supplemental Data
Supplemental Data include two Supplemental Figures and are
available with this article online at: http://www.current-biology.
com/cgi/content/full/15/18/1629/DC1/.
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